Brief: Galapagos Initiates Late Stage Study With Filgotinib In Patients With Active Axial Spondyloarthritis
02/05/2023 23:32
May 2 (Reuters) - Galapagos NV GLPG.AS :
* GALAPAGOS INITIATES PHASE 3 PROGRAM WITH FILGOTINIB IN
PATIENTS
WITH ACTIVE AXIAL SPONDYLOARTHRITIS
Further company coverage: GLPG.AS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors